$TLRY

FALTISCHEK DENISE M purchased $12K of TLRY

FALTISCHEK DENISE M (Chief Strategy Officer) purchased 2,500 shares of Tilray Brands, Inc. (TLRY) at $4.78 on 2026-08-03.

Original reporting
SEC EDGAR · FALTISCHEK DENISE M
Published Aug 4, 2026, 2:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 4, 2026, 3:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TLRY
Bullish
medium confidence
Mentioned
$TLRY
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TLRYBullishLow
01

Why it matters

A new insider open-market purchase was reported, which can slightly influence sentiment but does not change fundamentals on its own.

02

Market read

Traders may note the insider buy, but the disclosed value is small and there is no accompanying corporate catalyst.

03

What to watch

No 10b5-1 plan is cited, but the filing does not explain motivation, timing constraints, or whether the buy is part of a broader pattern.

Relevance 4/10Novelty 3/10Timing: SEC Form 4 filed today, after-hours/late session visibility

Background

This is an SEC Form 4 insider transaction disclosure for Tilray Brands, Inc.

Company-level read

Ticker impact

$TLRYBullishMedium confidence
Context

Tilray Brands disclosed via Form 4 that Chief Strategy Officer Denise M. Faltischek bought 2,500 shares at $4.7800 on 2026-08-03.

Expected impact

Likely limited near-term impact; may add small incremental bullish sentiment rather than a catalyst.

Evidence & confidence

Form 4 is primary-source and new today, but the transaction value (~$12k) is small relative to typical market-moving thresholds and provides no guidance, deal, or operational change.

Market effects

No clear sector read-through; this is company-specific insider activity without broader regulatory or industry developments.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity or diversification rather than a strong fundamental signal, especially at small sizes.

Key entities

  • Tilray Brands, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Denise M. Faltischek

    Chief Strategy Officer who purchased 2,500 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TLRYMed

Jefferies raises Tilray stock price target on brewing restructuring

Jefferies raised its price target on Tilray Brands (TLRY) to $13 from $12, maintaining a Reduce rating. The stock trades at $2.67, down 80% over the past year. Tilray is restructuring its U.S. brewing operations, targeting $20 million in annual savings by 2028. The company reported $257.1 million in Q1 fiscal 2027 revenue, up 23% year-over-year, but posted a net loss of $40 million.

$TLRYMed

Tilray Medical Gains Approval For In-House Quality Testing At Portugal Facility

Tilray Brands (TLRY) received approval from Portugal's INFARMED for in-house quality testing at its Cantanhede facility. This allows microbiological and chemical/physical testing on-site, improving control and speeding up product release. The company expects reduced costs and faster supply to key markets like Germany and the UK. TLRY's stock closed at $3.36, down 5.08%, and was down 0.30% in premarket trading.

$TLRYMed

Tilray Brands, Inc.: Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets

Tilray Medical, a division of Tilray Brands (TLRY), received approval from Portugal's INFARMED to conduct in-house quality testing at its Cantanhede facility. This allows for faster product release and strengthens its global medical cannabis supply chain, benefiting markets like Germany and the UK. The move is expected to reduce costs and improve efficiency, supporting Tilray's position as a leading medical cannabis supplier.

$TLRYLow

Should you sell your Tilray stock?

Tilray Brands (TSX:TLRY) reported fiscal Q1 2027 revenue of $257.1M and Adjusted EBITDA of $9.2M, missing analyst estimates. Cannabis revenue fell 13% year-over-year, while beverage alcohol revenue rose 82.1%. Analyst Neal Gilmer maintained a 'Hold' rating and $4.00 target, citing concerns about organic growth and cash flow.